Highly potent inhibitors of TNF-α production. Part I: Discovery of new chemical leads and their structure-activity relationships

Bioorganic and Medicinal Chemistry

Volumn 10, Issue 12, 2002, Pages 3757-3786

  Matsui, Toshiaki ^a   Kondo, Takashi ^a   Nishita, Yoshitaka ^a   Itadani, Satoshi ^a   Nakatani, Shingo ^a   Omawari, Nagashige ^a   Sakai, Masaru ^a   Nakazawa, Shuichi ^a   Ogata, Akihito ^a   Mori, Hideaki ^a   Terai, Kouichiro ^a   Kamoshima, Wataru ^a   Ohno, Hiroyuki ^a   Obata, Takaaki ^a   Nakai, Hisao ^a   Toda, Masaaki ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1,3 DIOXAINDAN 4 YL) 2 OCTANOYLAMINOETHYLDISODIUM; 2 (1,3 DIOXAINDAN 5 YL) 2 OCTANOYLAMINOETHYLDISODIUM; 2 (3 ETHOXYPHENYL) 2 OCTANOYLAMINOETHYLDISODIUM PHOSPHATE; 2 (3 ISOPROPYLOXYPHENYL) 2 OCTANOYLAMINOETHYLDISODIUM PHOSPHATE; 2 (3 METHOXYPHENYL) 2 OCTANOYLAMINOETHYLDISODIUM PHOSPHATE; 2 (NAPHTHALEN 1 YL) 2 OCTANOYLAMINOETHYLDISODIUM PHOSPHATE; 2 (NAPHTHALEN 2 YL) 2 OCTANOYLAMINOETHYLDISODIUM PHOSPHATE; 2 (OCTANOYLAMINO) 2 PHENYLETHYLDISODIUM PHOSPHATE; 2 OCTANOYLAMINO 2 (THIOPHEN 2 YL)ETHYLDISODIUM PHOSPHATE; ANTIINFLAMMATORY AGENT; LIPOPOLYSACCHARIDE; PROTEIN SYNTHESIS INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG STRUCTURE; LIVER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; SPLEEN; STRUCTURE ACTIVITY RELATION;

ANIMALS; FEMALE; INDANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED BALB C; ORGANOPHOSPHORUS COMPOUNDS; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036979119     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00381-4     Document Type: Article

References (41)

1. Tracey K.J., Cerami A. Annu. Rev. Med. (45):1994;491.
2. Bemelmans M.H., van Tits L.J., Buurman W.A. Crit. Rev. Immunol. 16:1996;1.
3. Aggarwal B.B., Kohr W.J., Hass P.E., Moffat B., Spencer S.A., Henzel W.J., Bringman T.S., Nedwin G.E., Goeddel D.V., Harkins R.N. J. Biol. Chem. 260:1985;2345.
4. Camussi G., Lupia E. Drugs. 55:1998;613.
5. Tilg H. Can. J. Gastroenterol. 15:2001;661.
6. Jacobs R.F., Tabor D.R. Scand. J. Infect. Dis. Suppl. 73:1990;7.
7. Arrieta O., Rodriguez-Reyna T.S., Sotelo J. Exp. Opin. Ther. Patents. 10:2000;601.
8. Blam M.E., Stein R.B., Lichtenstein G.R. Am. J. Gastroenteral. 96:2001;1977.
9. Assche V.G., Rutgeerts P. Exp. Opin. Invest. Drugs. 9:2000;103.
10. Marriott J.B., Westry M., Dalgleish A.G. Drug Disc. Today. 2:1997;273.
11. Nelson F.C., Zask A. Exp. Opin. Invest. Drugs. 8:1999;383.
12. Lowe C. Exp. Opin. Ther. Patents. 8:1998;1309.
13. Shire M.G., Muller G.W. Exp. Opin. Ther. Patents. 8:1998;531.
14. Matsui T., Kondo T., Nishita Y., Itadani S., Nakatani S., Omawari N., Sakai M., Nakazawa S., Ogata A., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. Lett. 12:2002;903.
15. Matsui T., Kondo T., Nishita Y., Itadani S., Tsuruta H., Fujita S., Omawari N., Sakai M., Nakazawa S., Ogata A., Mori H., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. Lett. 12:2002;907.
16. Steiger R.E. Org. Synth. III:1995;84.
17. (a) Rasolonjaatovo I., Sarfati S.R. Nucleosides & Nucleotides. 17:1998;. 2021 and references cited therein.
18. Dolle R.E., Schmidt S.J., Kruse L.I. J. Chem. Soc., Chem. Commun. 1987;904.
19. Bannwarth W., Trzeciak A. Helvetica Chimica Acta. 70:1987;175.
20. Lee V., Newman M.S. Org. Synth. VI:1988;613.
21. Rodighiero P., Pastorini G., Chilin A., Marotto A.J. Heterocycl. Chem. 35:1998;847.
22. Wolfe J.P., Åhman J., Sadighi J.P., Singer R.A., Buchwald S.L. Tetrahedron Lett. 38:1997;6367.
23. (a) Chag H-T., Sharpless K.B. Tetrahedron Lett. 37:1996;3219 (b) Kolb H.C., VanNieuwenhze M.S., Sharpless K.B. Chem. Rev. 94:1994;2483.
24. (a) Chag H-T., Sharpless K.B. Tetrahedron Lett. 37:1996;3219 (b) Kolb H.C., VanNieuwenhze M.S., Sharpless K.B. Chem. Rev. 94:1994;2483.
25. Scheit K.-H. Biochim. Biophys. Acta. 157:1968;632.
26. Dolfini, J. E. US Patent 4000134, 1976.
27. Davies A.J., Ashwood M.S., Cottrell I.F. Synthetic Communications. 30:2000;1095.
28. (a) Suzuki S., Nakamura S., Serizawa A., Sakaguchi T., Konno H., Muro H., Kosugi I., Baba S. Hepatolory. 24:1996;219 (b) Giroir B.P., Johnson J.H., Brown T., Allen G.L., Beutler B. J. Clin. Invest. 90:1992;693 (c) Beutler B.A., Milsark I.W., Cerami A. J. Immunol. 135:1985;3972.
29. (a) Suzuki S., Nakamura S., Serizawa A., Sakaguchi T., Konno H., Muro H., Kosugi I., Baba S. Hepatolory. 24:1996;219 (b) Giroir B.P., Johnson J.H., Brown T., Allen G.L., Beutler B. J. Clin. Invest. 90:1992;693 (c) Beutler B.A., Milsark I.W., Cerami A. J. Immunol. 135:1985;3972.
30. (a) Suzuki S., Nakamura S., Serizawa A., Sakaguchi T., Konno H., Muro H., Kosugi I., Baba S. Hepatolory. 24:1996;219 (b) Giroir B.P., Johnson J.H., Brown T., Allen G.L., Beutler B. J. Clin. Invest. 90:1992;693 (c) Beutler B.A., Milsark I.W., Cerami A. J. Immunol. 135:1985;3972.
31. 2.
32. 2.
33. 2.
34. 11I, (iii) TsOH, MeOH, (iv) Jone's oxidation.
35. 7Br, (iii) TsOH, MeOH, (iv) Jone's oxidation.
36. 5Br, (iii) TsOH, MeOH, (iv) Jone's oxidation.
37. 5Br, (iii) TsOH, MeOH, (iv) Jone's oxidation.
38. Dibenzylphosphorochloridate was prepared from benzyl phenoxymethylphosphinate according to the following paper and used as 1 M stock solution: Kenner, G. W.; Todd, A. R.; Weymouth, F. J. J. Chem. Soc. 1952, 3675.
39. Khorana H.G., Todd A.R. J. Chem. Soc. 1953;2257.
40. Gajda T., Zwierzak A. Synthesis. 1976;243.
41. David S.A., Silverstein R., Amura C.R., Kielian T., Morrison D.C. Antimicrob. Agents Chemother. 43:1999;912.